Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Métodos compatibles con Buenas Prácticas de Manufactura para producir músculo cardíaco con ingeniería tisular a partir de células madre

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TODE20160926002
Publicado:
19/10/2016
Caducidad:
19/10/2017
Resumen:
Científicos de una universidad alemana han desarrollado dos métodos nuevos y totalmente definidos para la producción sin suero de músculos cardíacos con ingeniería tisular a partir de cardiomiocitos prediferenciados o directamente de células madre indiferenciadas. Estos métodos permiten producir músculos cardíacos humanos bajo las estrictas normas de GMP (Buenas Prácticas de Manufactura). La ingeniería de tejidos puede emplearse en detección in vitro (detección de medicamentos o toxicología) o como herramienta terapéutica para sustituir tejidos dañados o enfermos (medicina regenerativa). La universidad busca socios para utilizar la plataforma de detección de medicamentos y continuar con el desarrollo en un enfoque de medicina regenerativa.

Details

Tittle:
GMP-compatible Methods for producing tissue-engineered human heart muscle from stem cells
Summary:
Scientists at a German University developed two new and fully defined methods for serum-free production of human engineered heart muscles (EHM) either from pre-differentiated cardiomyocytes or directly from undifferentiated stem cells. This will allow production of human EHM under strict GMP (Good Manufacturing Practices) standards. The University is looking for in-licensing partners for use as drug screening platform and/or for further development into a regenerative medical approach.
Description:
A major challenge in tissue engineering is the need for methods using clearly defined and GMP-compatible compounds. Furthermore, laboratory-grown tissue should resemble the natural organ´s tissue as closely as possible, especially with respect to its physiological function to qualify as a versatile tool in drug development and/or surrogate tissue for organ repair. Its successful industrial application will require tissue assembly under GMP-compatible protocols.

Scientists at the German University developed two new and fully defined methods for serum-free production of human engineered heart muscles (EHM) either from pre-differentiated cardiomyocytes or directly from undifferentiated stem cells. This will allow production of human EHM under strict GMP standards.
Heart tissue engineering using stem cells is a recently developed technique to construct a three dimensional structure from cardiomyocytes or directly from progenitor cells. Those engineered tissues can be either used for in vitro screenings (e.g. drug or toxicology screenings) or as a therapeutic tool to replace damaged or diseased tissue (regenerative medicine).

The University is looking for in-licensing partners for use as drug screening platform and/or for further development into a regenerative medical approach.
Advantages and Innovations:
- Generation of human EHM under GMP conditions using stem cell-derived material.
- Two well-defined protocols for different starting materials:
a) pre-differentiated myocytes and non-myocytes
b) homogeneous population of undifferentiated progenitor cells.
- human EHM have similar physiological properties to human myocardium.

The developed methods can be used:
- In vitro for:
a) Toxicity Screening with special emphasis on cardiac side effects such as arrhythmia, muscle damage, fibrosis, atrophy, hypertrophy, apoptosis, and contractile failure.
b) Drug Screening for biological activity of lead compounds and identification of mechanism of action.
- In vivo for:
a) Regenerative Medicine (replacement therapy of damaged heart myocardium).
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted

Partner sought

Type and Role of Partner Sought:
- Type of partner sought: Industry.

- Specific area of activity of the partner: Companies active in the field of tissue engineering related to cardiology.

- Task to be performed by the partner sought:
Further use in drug screening and toxicity platforms. Further development into regenerative medicine for human heart patients.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
German

Keywords

Technology Keywords:
06002007 Ensayos in vitro, experimentos
06001002 Investigaciones clínicas, ensayos
06001007 Medicina de urgencias
06004 Micro y nanotecnología relacionada con las ciencias biológicas